Holen Sie sich die Stockscreener-App
1.38
5.48%
-0.08
Vorhandelsmarkt:
1.31
-0.07
-5.07%
Schlusskurs vom Vortag:
$1.46
Offen:
$1.44
24-Stunden-Volumen:
553.31K
Relative Volume:
0.85
Marktkapitalisierung:
$92.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-46.12M
KGV:
-1.5969
EPS:
-0.8642
Netto-Cashflow:
$-41.02M
1W Leistung:
-16.87%
1M Leistung:
-12.66%
6M Leistung:
-20.23%
1J Leistung:
-12.66%
1-Tages-Spanne:
$1.32
$1.48
1-Wochen-Bereich:
$1.30
$1.65
52-Wochen-Spanne:
$0.7113
$2.815
Inflarx N V Stock (IFRX) Company Profile
Vergleichen Sie IFRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
1.38 | 98.91M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-29 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-02-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-10-28 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-06 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-04-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-05 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-06-05 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-01-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-10 | Eingeleitet | Credit Suisse | Outperform |
| 2018-07-13 | Eingeleitet | BMO Capital Markets | Outperform |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-28 | Eingeleitet | SunTrust | Buy |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Inflarx N V Aktie (IFRX) Neueste Nachrichten
InflaRx N.V. stock prediction for this weekJuly 2025 Decliners & Low Drawdown Investment Strategies - newser.com
Will InflaRx N.V. stock see PE expansionWeekly Trade Analysis & Consistent Profit Trade Alerts - newser.com
Will InflaRx N.V. (IF0) stock outperform benchmarksWeekly Trend Summary & Safe Entry Point Alerts - newser.com
Why InflaRx N.V. (IF0) stock benefits from AI revolutionJuly 2025 Trends & Weekly Setup with ROI Potential - newser.com
Why InflaRx N.V. stock is considered a top pickJuly 2025 Patterns & Verified Chart Pattern Trade Signals - newser.com
Why InflaRx N.V. stock remains a top recommendationTrade Entry Summary & Detailed Earnings Play Strategies - newser.com
What hedge fund moves indicate for InflaRx N.V. (IF0) stockTrade Entry Report & Fast Exit and Entry Strategy Plans - newser.com
Can InflaRx N.V. recover in the next quarter2025 Trading Recap & Risk Controlled Swing Alerts - newser.com
Will InflaRx N.V. (IF0) stock deliver compounding returnsJuly 2025 PreEarnings & Real-Time Price Movement Reports - newser.com
What makes InflaRx N.V. stock attractive to growth fundsTrade Exit Report & Verified Swing Trading Watchlists - newser.com
How geopolitical tensions affect InflaRx N.V. stockBear Alert & Risk Managed Investment Strategies - newser.com
Institutional scanner results for InflaRx N.V.Weekly Market Report & Daily Technical Stock Forecast Reports - newser.com
Total debt per share of InflaRx N.V. – MUN:IF0 - TradingView
Reversal indicators forming on InflaRx N.V. stock2025 Sector Review & Daily Chart Pattern Signal Reports - newser.com
How InflaRx N.V. stock performs after earningsGap Up & Safe Capital Allocation Plans - newser.com
Volatility clustering patterns for InflaRx N.V.Recession Risk & Technical Pattern Recognition Alerts - newser.com
InflaRx NV IF0 Stock Analysis and ForecastEarnings Growth Projections & Learn to Think Like a Long-Term Investor - earlytimes.in
InflaRx N.V. (NASDAQ:IFRX) Short Interest Update - MarketBeat
How reliable is InflaRx N.V. (IF0) stock dividend growthIPO Watch & Daily Profit Maximizing Tips - newser.com
Can InflaRx N.V. stock rebound after recent weaknessTrade Volume Summary & Daily Chart Pattern Signals - newser.com
Will InflaRx N.V. (IF0) stock deliver stable dividends2025 Winners & Losers & High Win Rate Trade Tips - newser.com
Edesa Biotech and InflaRx: Advancing ARDS Treatment with Vilobelimab - MSN
InflaRx’s Phase 2a Study on INF904: A Potential Game-Changer for Chronic Conditions - MSN
Edesa Biotech and InflaRx: Breathing New Life into ARDS Treatment - MSN
InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why InflaRx N.V. stock remains resilient2025 Investor Takeaways & Weekly Watchlist for Consistent Profits - fcp.pa.gov.br
Edesa Biotech and InflaRx: Advancing ARDS Treatment with Bevacizumab - MSN
Finanzdaten der Inflarx N V-Aktie (IFRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):